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 Translational Relevance  
Tepotinib is a potent, highly selective MET inhibitor. In this first-in-man trial, 
tepotinib was shown to be well-tolerated and active against solid tumors, particularly 
those expressing high levels of MET. Tepotinib proved well-tolerated up to the 
highest dose administered (1400 mg once daily), while a recommended phase II 
dose of 500 mg once daily was defined based on a translational modeling approach 
integrating preclinical pharmacokinetic, target modulation, and efficacy data, along 
with clinical pharmacokinetic and tumor target modulation data. Taken together, the 
results support exploring tepotinib for the treatment of patients with non-small cell 
lung cancer whose tumors are either driven by MET alterations, including MET exon 
14-skipping, or in which MET is implicated in secondary resistance to epidermal 
growth factor receptor inhibitors.   
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Abstract 
Purpose: Tepotinib is an oral, potent, highly selective MET inhibitor. This first-in-
man phase I trial investigated the maximum tolerated dose (MTD) of tepotinib to 
determine the recommended phase II dose (RP2D). 
Patients and Methods: Patients received tepotinib orally according to one of 
three dose-escalation regimens (R) on a 21-day cycle: R1, 30–400 mg once daily for 
14 days; R2, 30–315 mg once daily 3 x /week; or R3, 300–1400 mg once daily. After 
two cycles, treatment could continue in patients with stable disease until disease 
progression or unacceptable toxicity. The primary endpoint was incidence of dose-
limiting toxicity (DLT) and treatment-emergent adverse events (TEAEs). Secondary 
endpoints included safety, tolerability, pharmacokinetics, pharmacodynamics, and 
antitumor effects. 
Results: 149 patients received tepotinib (R1: n = 42; R2: n = 45; R3: n = 62). 
Although six patients reported DLTs (one patient in R1 [115 mg], three patients in R2 
[60, 100, 130 mg], two patients in R3 [1000, 1400 mg]), the MTD was not reached at 
the highest tested dose of 1400 mg daily. The RP2D of tepotinib was established as 
500 mg once daily, supported by translational modeling data as sufficient to achieve 
≥95% MET inhibition in ≥90% of patients. Treatment-related TEAEs were mostly 
grade 1 or 2 fatigue, peripheral edema, decreased appetite, nausea, vomiting, and 
lipase increase. The best overall response in R3 was partial response in two 
patients, both with MET overexpression. 
Conclusions: Tepotinib was well-tolerated with clinical activity in MET-
dysregulated tumors. The RP2D of tepotinib was established as 500 mg once daily.  
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Statement of Significance  
MET abnormalities can drive tumorigenesis. This first-in-man trial demonstrated 
that the potent, highly-selective MET inhibitor tepotinib can reduce or stabilize tumor 
burden and is well-tolerated at doses up to 1400 mg once daily. A recommended 
phase II dose of 500 mg once daily, as determined from translational modeling and 
simulation integrating human population pharmacokinetic and pharmacodynamic 
data in tumor biopsies, is being used in ongoing clinical trials. 
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Introduction 
MET receptor tyrosine kinase activation increases cellular proliferation, survival, 
mobilization, and invasive capacity (1,2). Chronic MET activation in advanced solid 
tumors occurs via mechanisms including activating MET mutations (3), MET 
amplification (4), and overexpression of MET or its ligand hepatocyte growth factor 
(HGF) (5,6). Activated MET can drive tumorigenesis (7) and make tumors resistant 
to epidermal growth factor receptor (EGFR) inhibitors, vascular endothelial growth 
factor inhibitors, and anti-human EGFR-2 therapies (1). Tumor MET activity is also 
associated with aggressive cancer phenotypes (8) and poor prognosis (9,10). MET 
inhibitors may, therefore, have a role in cancer therapy (11,12).  
Tepotinib is an oral, highly selective and potent MET inhibitor that inhibits MET 
phosphorylation and downstream signaling. The 50% inhibitory concentration (IC50) 
of MET was determined as 1.7 nM, and screening against >400 kinases showed 
high selectivity of tepotinib for MET. Tepotinib inhibits both HGF-dependent 
and -independent MET kinase activity, providing greater suppression of MET 
signaling than inhibitors of only ligand-dependent activity (13). In preclinical studies, 
tepotinib inhibited the growth of MET-dependent human xenograft tumors and 
cancer explants (14-17). This phase I first-in-man study was conducted to establish 
the recommended phase II dose (RP2D) of tepotinib in patients with advanced solid 
tumors. 
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Patients and Methods 
Study design and treatment 
This open-label, non-randomized, dose-escalation phase I trial in patients with 
advanced solid tumors (ClinicalTrials.gov ID: NCT01014936) was conducted in 
compliance with the Declaration of Helsinki, the International Council for 
Harmonisation Tripartite Guideline for Good Clinical Practice, and all applicable 
regulatory requirements. The institutional review board for each site approved the 
study and all patients provided written informed consent to participate. 
Dose-escalation used a classic 3+3 design. Patients received one of three 
tepotinib regimens (R) on a 21-day cycle (Fig. 1A). Patients were alternately 
assigned to R1 or R2 until R3 was introduced based on emerging clinical data from 
the trial, when R1 was discontinued and patients were alternately assigned to R2 or 
R3. Dose escalation was guided by the occurrence of dose-limiting toxicity (DLT) 
and grade 2 clinically relevant treatment-emergent adverse events (TEAEs). If no 
grade ≥2 TEAEs were observed, 100% dose increments were applied; otherwise, 
lesser increments were applied. Patients received tepotinib until disease 
progression, unacceptable toxicity, or withdrawal of consent. After dose-escalation, 
an additional cohort of 12 patients with MET amplification and a cohort of 12 patients 
with MET overexpression were enrolled at the RP2D. 
Tepotinib was supplied in three formulations: non-micronized in capsules (initial 
formulation [IF]); micronized in capsules (optimized formulation [OF]); and 
micronized in tablet form. Patients received one type of formulation (micronized or 
non-micronized), with their daily dose comprising multiple capsules or tablets of 15 
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mg to 100 mg to reach the required dose. The tablet formulation was given 
exclusively to patients in R3.  
The primary objective was to determine the maximum tolerated dose (MTD) of 
tepotinib for each regimen in patients with solid tumors. Secondary objectives 
included safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and 
antitumor activity of tepotinib. If it was determined impossible or unnecessary to 
establish an MTD in a given regimen, an RP2D would be established.  
Patients  
Patients had measurable or evaluable solid tumors, either refractory to standard 
therapy or for which no effective standard therapy was available, Eastern 
Cooperative Oncology Group performance status 0–2, and adequate hematological, 
liver and renal function. MET status was not used for initial recruitment, while 
patients in the RP2D expansion cohort (R3) required either MET amplification or 
MET overexpression. Patients who had received systemic anticancer therapy within 
28 days of trial treatment or prior radiotherapy to >30% of bone marrow were 
ineligible. See Supplementary Information for full inclusion and exclusion criteria. 
Assessments 
Patients were monitored for toxicity throughout the trial. TEAEs were graded 
using the National Cancer Institute’s Common Terminology Criteria for Adverse 
Events (NCI-CTCAE) v4.0. A DLT was defined as one of the following TEAEs 
observed during cycle 1, regardless of tepotinib relationship: grade 4 neutropenia >7 
days; grade ≥3 febrile neutropenia for >1 day; grade 4 thrombocytopenia or grade 3 
with bleeding; grade ≥3 nausea and vomiting despite optimal treatment; grade ≥3 
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non-hematological TEAE (except nausea and vomiting with no adequate treatment, 
and alopecia); grade ≥3 liver event requiring >7 days recovery to baseline or to 
grade ≤1 for patients without liver metastases or to grade ≤2 for those with 
metastases; grade ≥3 lipase and/or amylase rise with pancreatitis confirmation; or 
any other event that caused a delay of >21 days in planned tepotinib administration 
due to prolonged recovery to grade ≤1 or baseline status. TEAEs assessed by the 
investigator to be exclusively related to the patient’s underlying disease or medical 
condition were not considered DLTs. The MTD was defined as the dose level below 
that at which two of three patients or two of six patients (depending on the size of the 
cohort) experienced a DLT. 
Tumors were assessed at baseline and the end of every second cycle by 
radiography, computed tomography, or magnetic resonance imaging. Tumor 
response assessments were based on Response Evaluation Criteria in Solid Tumors 
version 1.0; best overall response (BOR) was assessed between baseline and 
disease progression. Partial (PR) and complete responses were confirmed 6 weeks 
after first evaluation.  
Pharmacokinetics 
Blood samples were taken for PK analysis during cycle 1 (R1 and R3: up to 24 
hours post-dose days 1 and 14, and pre-dose days 3, 8, and 17; R2: up to 48 hours 
post-dose days 1 and 19 and pre-dose days 3 and 8). Additional blood samples were 
taken pre-dose on day 1 of each subsequent cycle for all regimens. Standard non-
compartmental methods were used to calculate PK parameters using WinNonlin 
(version 6.3, Certara INC, Princeton, USA). Effects of food on the PK characteristics 
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of tepotinib were explored in R1 and R2 patient subsets. The bioavailability of 
capsule and tablet formulations was compared for tepotinib 500 mg dosing. 
Differences in area under the plasma concentration curve (AUC) and observed 
maximum plasma concentration (Cmax) between groups (fed vs. fasted, tablet vs. 
capsule) were assessed using analysis of variance (ANOVA) and differences in time 
to reach the maximum plasma concentration (tmax) by computing the Hodges–
Lehmann shift estimate. Dose proportionality was assessed using ANOVA. 
Human PK profiles, including 2914 data points from 419 patients who received 
tepotinib 30–1400 mg orally once daily, were analyzed with compartmental models 
using a population approach. The population PK model characterized both the dose–
plasma concentration relationship of tepotinib after oral administration in humans, 
and the associated PK variability between individuals and the intrinsic/extrinsic 
factors predictive of such variability. Further details on population PK modeling are 
included in the Supplementary Information.  
Biomarkers 
Paired tumor biopsies for MET status and PD biomarker assessment were 
performed when possible and were required from all patients recruited after October 
15, 2010 unless archived tumor samples were available. The first biopsy was taken 
during screening, and the second between days 9 and 14 of cycle 1 (R1), or days 17 
and 21 of cycle 1, or, if continuing treatment, on day 1 of cycle 2 (R2 and R3). A 
LuminexTM assay was used to assess total MET and phosphorylated MET (phospho-
MET) as described in the Supplementary Information. Blood samples for PD 
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assessment were taken on days 1, 3, 8, 14, and 17 (R1 and R3), and days 1, 3, 8, 
and 19 (R2) of cycle 1. 
Tumor MET status was assessed for MET overexpression using 
immunohistochemistry (IHC) and for MET amplification using in situ hybridization 
(ISH) or next-generation sequencing. For IHC, MET antibodies D1C2 (Cell Signaling 
Technology) and SP44 (Roche/Ventana) were used. Tumors were classified as 
overexpressing MET if >50% of cells showed strong MET staining (3+ on a scale of 
0–3+; MET IHC3+); otherwise, they were classified as MET IHC≤2. For ISH, MET 
and CEP7 probes were used, with MET amplification defined as a mean MET:CEP7 
ratio ≥2, or clusters of >5 MET copies in >10% of tumor nuclei (>50 nuclei counted). 
MET amplification was also determined by a next-generation sequencing-based 
method (Foundation Medicine, Cambridge, USA) on either archived or fresh pre-
treatment tumor biopsies. 
Statistical plan 
Statistical determination of sample size was unnecessary as the protocol 
followed a classic 3+3 design. The primary endpoint was the incidence of DLTs 
occurring during the first treatment cycle and treatment-related TEAEs. Summary 
statistics (means, medians, ranges, and appropriate measures of variability) were 
calculated for each dose level. Secondary endpoints included safety, tolerability, PK, 
PD, and antitumor activity. All statistical analyses are regarded as exploratory. 
Model-informed selection of the recommended Phase II dose 
Preclinical PK/PD model simulations were performed to evaluate the correlation 
between target inhibition and tumor growth inhibition (TGI) as measured by the 
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tumor volume (T) of treated groups in relation to control (C; % T/C). Consequently, a 
PD criterion for the level of tumor MET phosphorylation inhibition associated with 
tumor regression was introduced to guide the clinical dose selection. PK and PD 
bioanalytical assays, together with full details of modeling of preclinical and human 
data, are presented in Fig. 1B, as well as in the Supplementary Information and Fig. 
S1.  
The KP-4 human pancreatic ductal cell carcinoma cell line (RCB1005; Riken Cell 
Bank, Japan) was used to generate xenografts in BALB/c-nu/nu mice because it is 
considered representative of human tumors with MET pathway activation and 
sensitivity to MET inhibitors. Xenograft tumors were generated as previously 
reported (15). All animal studies were conducted at Merck KGaA, Darmstadt, 
Germany, in compliance with the institutional ethical guidelines. Tepotinib was 
produced at Merck KGaA, Darmstadt, Germany, and prepared for oral 
administration, as previously described (18). The effect of tepotinib on KP-4 
xenograft-bearing mice was determined in a short-term (1–4 day) PK/PD study and 
longer-term (10–16 day) efficacy studies. In the preclinical PK/PD study, target 
inhibition was assessed according to phospho-MET modulation in xenograft tumors; 
in TGI studies, tumor size was measured. Longitudinal PK and PD measurements 
from KP-4 tumor-bearing mice in these studies, and clinical PD assessments based 
on paired biopsies (pre- and on-treatment) from patients in the first-in-man study 
(NCT01014936) were then integrated into mathematical models. This translational 
modeling approach enabled the prediction of an effective dose in humans, targeting 
a phospho-MET level that was relevant for preclinical efficacy. 
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To investigate plasma PK and tumor target inhibition, (phospho-MET), KP-4 
xenograft-bearing mice (five per group) were randomly assigned to receive a single 
dose of tepotinib (5, 15, 50, or 200 mg/kg) or vehicle by oral gavage when xenograft 
tumors reached 250–600 mm3. Blood and tumor samples were collected 0.5, 2, 6, 
12, 24, 48, and 72 hours post-dose. Plasma was prepared from blood by 
centrifugation at 9000 rpm at 4°C for 5 min and stored at –20°C for subsequent 
tepotinib analysis. 
Two experiments assessed the effects of tepotinib on TGI. In the first 
experiment, KP-4 xenograft-bearing mice (10 per group) were randomly assigned to 
receive tepotinib at 25, 50, or 200 mg/kg/day, or vehicle for 15 days (starting on day 
0) by oral gavage when the xenograft tumors reached 80–300 mm3. Tumor volume 
was assessed on days 0, 3, 6, 10, 13, and 16. In the second study, KP-4 xenograft-
bearing mice received tepotinib at 5, 15, 25, and 200 mg/kg/day, or vehicle for 10 
days. Tumor volume was assessed on days 0, 3, 7, and 10. Tumor volume was 
calculated as l*w2/2, where l = length of the longest axis of the tumor, and w = 
perpendicular width.  
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Results 
Patient characteristics and disposition 
Overall, 203 patients were screened at four sites: MD Anderson Cancer Center, 
Houston, Texas; University of Chicago Medical Center, Chicago, Illinois; Roswell 
Park Medical Center, Buffalo, New York, USA; and Universitätsklinikum Köln, 
Cologne, Germany. One-hundred-and-forty-nine patients were enrolled between 
November 2009 (first patient screened) and October 2015 (last patient last visit). The 
database was locked for final analysis on February 15, 2016.  
Table 1 shows baseline patient and tumor characteristics. Patients were initially 
treated orally with nonmicronized tepotinib in R1 (30–230 mg once daily for 14 days) 
and R2 (30–115 mg once daily 3 x/week for 3 weeks). Following a protocol 
amendment, dosing was switched from nonmicronized tepotinib to micronized 
tepotinib capsules. Subsequently, patients received micronized tepotinib capsules in 
R1 (30–400 mg once daily for 14 days) and R2 (60–315 mg once daily 3 x/week for 
3 weeks). In R3, patients received micronized tepotinib capsules (300–1400 mg 
once daily for 3 weeks). After the introduction of R3, R1 ceased enrollment. An 
additional cohort of 12 patients with MET amplification and a cohort of 12 patients 
with MET overexpression were included in R3 and received micronized tepotinib 500 
mg orally, once daily. The tablet formulation of micronized tepotinib was introduced 
for testing at the 500 mg dose level in R3; in total, 42 patients received tepotinib 500 
mg. Dosing above 1400 mg daily was limited by pill burden. 
Overall, 149 patients received treatment with a median time on treatment of 6.0 
weeks for each regimen: 42 patients on R1 (range 2.1–153.3 weeks), 45 patients on 
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R2 (range 1.0–27.6 weeks), and 62 patients on R3 (range 0.7–94.9 weeks). In the 
500 mg cohort, the median time on treatment was 6.0 weeks (range 0.7–42.4 
weeks). Full details of time on treatment for all dose cohorts are shown in 
Supplementary Table S1. 
Safety  
Six patients reported DLTs: in R1, one patient (115 mg IF) had asymptomatic 
grade 4 lipase and grade 3 amylase increase; in R2, two patients (60 and 100 mg 
OF) had asymptomatic grade 3 lipase increase (one with a prior history of elevated 
lipase and transaminases), and one (130 mg OF) had grade 3 nausea and vomiting; 
and in R3, one patient (1000 mg OF) had grade 3 alanine aminotransferase (ALT) 
increase and one (1400 mg OF) grade 3 fatigue. The MTD was not reached at the 
maximum tested dose of 1400 mg once daily (R3).  
Most (97.3%) patients experienced at least one TEAE. TEAEs led to permanent 
tepotinib treatment discontinuation for 20 (13.4%) patients. Seventy-six (51.0%) 
patients experienced treatment-related TEAEs (Table 2), most frequently grade 1/2 
fatigue, peripheral edema, decreased appetite, nausea, vomiting, and lipase 
increase. Treatment-related grade ≥3 TEAEs occurred in 13 (8.7%) patients and led 
to discontinuation in three (2.0%) patients (one in R1 and two in R3). Most treatment-
related TEAEs resolved without intervention. There were no treatment-related 
TEAEs leading to death. Overall, there was a higher frequency of treatment-related 
TEAEs reported in R3, where higher doses of tepotinib were administered. For the 
500 mg cohort (n = 42), incidence of any grade treatment-related TEAEs were 
similar to the overall study population, with the most common being peripheral 
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edema (11, 26.2%), fatigue (9, 21.4%) and decreased appetite (7, 16.7%) 
(Supplementary Table S2). Of the patients receiving tepotinib 500 mg, six (14.3%) 
and nine (21.4%) temporarily or permanently discontinued treatment due to TEAEs, 
respectively. Two (4.8%) patients in the 500 mg cohort had their dose reduced. 
Overall, 53 (35.6%) patients reported serious adverse events (SAEs). In one 
patient these were considered related to study treatment (grade 3 nausea and grade 
3 vomiting, R2). The most frequent SAEs in R3 were grade 2 or 3 gastrointestinal 
disorders. One patient (R3, tepotinib 500 mg once daily) died due to an SAE of 
hepatic failure recorded as disease progression unrelated to the study drug.  
Pharmacokinetics 
In fasting patients, the initial capsule formulation produced highly variable AUC 
and Cmax, so the formulation was optimized and administered with food. The 
following PK results were obtained in fed patients using the optimized formulation, 
including the 500 mg tablet formulation (see Supplementary Data, Tables S3, S4, 
S5, and S6). Tepotinib was absorbed slowly after the first dose, with a median tmax of 
8–10 hours. Increases in Cmax and AUC0–24h with increasing dose were observed 
after single and multiple dosing for both once daily and 3 x/week tepotinib 
administration. A dose-proportional increase in Cmax and AUC0–24h occurred for once-
daily doses ≤300 mg, with less than dose-proportional increases at higher doses. 
Apparent clearance at steady state (Clss/f) was stable for tepotinib doses ≤315 mg 
(Clss/f 11.35–24.50 L/h) but increased at doses ≥700 mg (Clss/f 35.24–40.92 L/h). 
Clss/f for the tablet formulation at 500 mg was estimated to be 26.43 L/h. Multiple 
dosing resulted in accumulation of tepotinib in all regimens.  
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Based on the median AUC0–24h accumulation ratio of 3.3 after multiple once-daily 
dosing (500 mg tablet formulation), the average effective t1/2 was estimated to be 
approximately 46 hours. Correspondingly small peak-to-trough fluctuations were 
observed at steady state, eg, patients receiving tepotinib 500 mg in tablet form 
exhibited fluctuations of 32.1% around the geometric mean Cav of 1097.9 ng/mL 
(Supplementary Table S4 and Supplementary Fig. S2).  
Steady-state exposure to tepotinib was increased for patients receiving 500 mg 
tepotinib as tablets vs. capsules, with geometric mean AUC0–24h and Cmax higher by 
37% and 38%, respectively. tmax was unaffected by formulation as assessed after the 
first dose.  
Clinical antitumor activity of tepotinib  
The BOR in R3 was PR in two patients (Table 3): a 77-year-old male with MET 
IHC3+ (MET not amplified) esophageal cancer who received tepotinib 500 mg once 
daily (tablet formulation); and a 56-year-old female with MET IHC3+ (MET not 
amplified) lung cancer who received tepotinib 1400 mg once daily and completed 32 
cycles of tepotinib treatment with a progression-free survival (PFS) time of 21.8 
months. Two further patients had unconfirmed PRs; one (R2; MET status unknown) 
had nasopharyngeal carcinoma and one (R3; MET amplified and MET IHC3+) had 
colorectal cancer. Thirty-four patients had a BOR of standard deviation (SD), 
including 12 in R3. The BOR according to MET status is shown in Table 4. The 
change in the sum of longest diameters of target lesions from baseline is shown in 
Supplementary Fig. S3. 
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Targeted pharmacokinetics and pharmacodynamic threshold 
In the preclinical efficacy studies, tumor control was observed in treatment 
groups receiving a daily dose of tepotinib ≥25 mg/kg (Fig. 2A). The Simeoni tumor 
growth model was found to adequately fit the treatment effects of tepotinib. 
Concentrations of tepotinib required to achieve 90% (EC90) to 95% (EC95) maximum 
tumor inhibition were estimated to be within the range 390–823 ng/mL in humans 
after correcting for protein binding differences (2.9% in mice and 1.6% in humans).  
The correlation plot of efficacy reflected by TGI vs. target modulation model-
predicted average phospho-MET inhibition suggested that regression in KP-4 
xenograft tumors corresponded to approximately 95% phospho-MET inhibition (Fig. 
2B). Therefore, a PD criterion of sustained nearly complete inhibition of phospho-
MET (greater than 95%) was introduced as the targeted PD threshold in phase II 
development.  
Clinical dose selection 
Population PD simulation was performed using the full inhibitory turnover Imax PD 
model driven by the concentrations simulated from the population PK model, 
including estimated PK and PD variability. Targeting the PD criterion of sustained 
close-to-complete (≥95%) phospho-MET inhibition in tumors, simulations suggested 
that a regimen of tepotinib 500 mg once daily could achieve the PD threshold in 90% 
of the population (Fig. 2C). The clinical PK data on day 14 show that at a tepotinib 
dose of 500 mg once daily in humans, the individual trough tepotinib concentrations 
were within or above the target range and the mean steady-state concentration is 
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above the range (390–823 ng/mL) as determined from KP-4 efficacy experiments 
(Supplementary Fig. S2). 
Both PK and PD evidence supported the selection of tepotinib 500 mg once daily 
as the RP2D, which was well tolerated in the first-in-man trial and expected to deliver 
clinical efficacy in the target population. Further results from the modeling of 
preclinical and human data are presented in Supplementary Fig. S4 and 
Supplementary Table S7.  
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Discussion 
This first-in-man study was conducted to establish the MTD of tepotinib in 
patients with advanced solid tumors, using a classic 3+3 dose-escalation design. We 
analyzed data from 149 patients treated according to three dose-escalation regimens 
(R1–3). Tepotinib treatment was well-tolerated up to 1400 mg but no MTD could be 
defined. We have used a translational modeling approach to establish the tepotinib 
RP2D for patients with solid tumors. Phospho-MET inhibition in human tumors was 
fitted to a turnover model structurally developed based on KP-4 xenograft tumor 
data. Based on tumor shrinkage and MET inhibition results from mice with KP-4 
xenografts, an active concentration range of tepotinib was predicted and scaled up to 
humans. Efﬁcacy and PD proﬁling in KP-4 xenograft tumors suggested that near-
complete inhibition of MET kinase activity (≥95% reduction in phospho-MET) is 
required to achieve tumor regression. Targeting this PD threshold, a biologically 
active dose of 500 mg once daily was proposed as the RP2D for tepotinib in patients 
with solid tumors. In addition, continuous daily dosing with 500 mg of tepotinib was 
predicted to achieve the target exposure range (390–823 ng/mL). This dose is 
predicted to achieve continuous ≥95% MET inhibition in 90% of the population. 
Steady-state concentration time profiles at the 500 mg dose level, both for the 
capsule and the tablet formulation, showed exposure beyond the threshold as shown 
in Supplementary Fig. S2, and dosing of 42 patients confirmed the safety and 
tolerability of tepotinib at the RP2D of 500 mg once daily. The translational approach 
applied here highlight the utility of integrating preclinical and emerging first-in-man 
clinical data to support RP2D selection. Further, the characterization of PK and PD 
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relationships in patients will allow doses and dose schedules to be modified for 
specific patient populations as appropriate. 
A limitation of translational modeling is that some equivalence between the 
preclinical and clinical settings must be assumed, particularly with respect to 
conservation of PK/PD/efficacy relationships, and the similarity of preclinical 
xenograft tumor models to human malignancies. In addition, cell-line xenograft 
tumors do not reflect the heterogeneity of tumors in patients, which may develop 
MET-independent clones. For a conservative estimate of the tepotinib dose-efficacy 
relationship, the pancreatic cancer model KP-4 was chosen. HGF/MET autocrine 
KP-4 tumors are sensitive to tepotinib treatment but require substantially high doses 
to provoke partial tumor regression (15). Moreover, KP-4 xenografts have allowed 
reasonable dose predictions to be made for MET inhibitors in the past, increasing 
confidence in their relevance as a model of MET-positive tumors (19). 
Among the several types of MET inhibitors in development, potent, selective MET 
inhibitors are most likely to deliver optimal inhibition of MET with an optimal benefit–
risk ratio. The potency of tepotinib reduces its effective dose, and its selectivity 
minimizes the risk of toxicity due to off-target kinase inhibition, increasing its 
therapeutic margin. The main TEAEs associated with tepotinib were grade 1 or 2 
peripheral edema, fatigue, decreased appetite, and nausea and vomiting. Some 
patients experienced increases in serum lipase, amylase, ALT, and aspartate 
aminotransferase, which are asymptomatic, and generally resolve without treatment 
modification. Clinical studies of selective MET inhibitors capmatinib and savolitinib 
also reported peripheral edema, decreased appetite, and nausea among the most 
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common treatment-related TEAEs (20,21). While the incidence of grade ≥3 
treatment-related TEAEs was highest in the cohort that received continuous daily 
tepotinib (R3), tepotinib was well-tolerated at the RP2D of 500 mg once daily with no 
DLTs and only two treatment-related TEAEs leading to discontinuation. The PK 
characteristics of tepotinib allow oral once-daily dosing, which assists compliance, 
and its long half-life ensures a small peak–trough variation over 24 hours, reducing 
the risk of toxicity at peak and suboptimal inhibition at trough. These PK 
characteristics also support steady target inhibition, and in conjunction with available 
safety and tolerability results, constitute a promising drug profile for tepotinib. 
Although preclinical studies suggested that MET alterations, either 
overexpression or more especially genetic alterations such as MET amplification, 
may trigger a tumor to become more sensitive to MET inhibitors (1), the majority of 
patients in this study were not selected according to MET status. This non-selected 
recruitment to the trial was primarily designed to investigate safety, tolerability, PK, 
and PD; nevertheless, antitumor activity was observed. The BOR was a PR in two 
patients with MET IHC3+ tumors and SD in 12 patients in R3. Although data are 
limited with only 16 patients with MET IHC3+ and nine patients with MET amplified 
tumors, the antitumor activity of tepotinib appeared greatest in patients with MET 
IHC3+ tumors.  
These data suggest that tepotinib warrants further investigation in cancer patients 
with MET dysregulation. Phase Ib/II trials of tepotinib 500 mg once daily in patients 
with MET-overexpressing hepatocellular carcinoma (NCT01988493 and 
NCT02115373) and non-small cell lung carcinoma (NSCLC) with MET alterations 
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(NCT01982955 and NCT02864992) have confirmed both the tolerability of tepotinib 
and demonstrated clinical activity (22-25). A pooled safety analysis of 260 patients 
who received tepotinib 500 mg in five phase Ib/II studies also showed the 500 mg 
dose to be generally well tolerated (26). In patients with MET-amplified EGFR-
mutant NSCLC with resistance to EGFR tyrosine kinase inhibitors, treatment with 
tepotinib plus gefitinib greatly improved outcomes vs. the chemotherapy control arm 
(PFS 16.6 vs. 4.2 months, hazard ratio [HR] 0.13 [90% confidence interval (CI), 
0.04–0.43]; overall survival 37.3 vs. 13.1 months, HR 0.09 [90% CI, 0.01, 0.54) (23). 
Interim data from an ongoing study of patients with NSCLC harboring MET exon 14-
skipping alterations reported an overall response rate of 45% to 55% (27). 
In summary, the RP2D of 500 mg tepotinib orally once daily is well-tolerated by 
patients with advanced solid tumors. This first-in-man trial also demonstrated that 
tepotinib can be administered safely up to 1400 mg/day. Patients with high-level 
MET-expressing tumors appear to benefit most from treatment, and additional 
clinical studies in patients with MET dysregulated tumors are ongoing.  
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Table 1. Baseline patient and tumor characteristics  
 
Regimen 1 
(n = 42) 
Regimen 2 
(n = 45) 
Regimen 3 
(n = 62) 
Total 
(N = 149) 
Median age, years 
(range) 
62.8  
(21.1–83.1) 
61.3  
(19.2–81.6) 
57.8  
(23.2–80.5) 
61.0 
(19.2–83.1) 
Male/female, n (%) 24 (57.1)/ 
18 (42.9) 
22 (48.9)/ 
23 (51.1) 
37 (59.7)/ 
25 (40.3) 
83 (55.7)/ 
66 (44.3) 
Race, n (%)     
 White 39 (92.9) 37 (82.2) 57 (91.9) 133 (89.3) 
 Black 2 (4.8) 4 (8.9) 2 (3.2) 8 (5.4) 
 Asian 1 (2.4) 2 (4.4) 3 (4.8) 6 (4.0) 
 Other 0 2 (4.4) 0 0 
ECOG PS, n (%)     
 0 8 (19.0) 6 (13.3) 9 (14.5) 23 (15.4) 
 1 33 (78.6) 36 (80.0) 48 (77.4) 117 (78.5) 
 2 1 (2.4) 3 (6.7) 4 (6.5) 8 (5.4) 
 3 0 (0) 0 (0) 1 (1.6) 1 (0.7) 
Location of primary 
tumor, n 
    
 Colorectal 13 10 5 28 
 Lunga 4 2 11 17 
 Esophagus 3 1 11 15 
 Breast 0 2 7 9 
 Ovaryb 0 5 2 7 
 Prostate 3 1 2 6 
 Liverc 2 1 3 6 
 Stomach 0 2 4 6 
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Regimen 1 
(n = 42) 
Regimen 2 
(n = 45) 
Regimen 3 
(n = 62) 
Total 
(N = 149) 
 Skin 2 1 0 3 
 Bone 0 1 2 3 
 Pancreas 1 1 1 3 
 Melanoma 0 2 0 2 
 Kidney 0 1 1 2 
 Bladder 1 0 1 2 
 Head and neck 1 0 0 1 
 Soft tissue 0 0 1 1 
 Otherd 12 15 11 38 
Tumor type, n     
 Adenocarcinoma 21 15 30 66 
 Melanoma 4 10 0 14 
 Sarcoma 2 4 5 11 
 Squamous cell 
 carcinoma 
2 2 1 5 
 Undifferentiated 
 carcinoma 
0 1 0 1 
 Other 13 13 26 52 
Measurable disease at 
baseline, n (%) 
39 (92.9) 42 (93.3) 59 (95.2) 140 (94.0) 
Median number of prior 
therapies (range) 
7 (2–22) 7 (1–25) 6 (1–15) 6 (1–25) 
MET expression by IHC, 
n (%) 
    
 MET IHC3+ 2 (4.8) 5 (11.1) 9 (14.5) 16 (10.7) 
 MET IHC≤2 19 (45.2) 22 (48.9) 32 (51.6) 73 (49.0) 
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Regimen 1 
(n = 42) 
Regimen 2 
(n = 45) 
Regimen 3 
(n = 62) 
Total 
(N = 149) 
 Not available 21 (50.0) 18 (40.0) 21 (33.9) 60 (40.3) 
MET amplification, n (%)     
 Amplified 0 0 9 (14.5) 9 (6.0) 
 Not amplified 17 (40.5) 20 (44.4) 34 (54.8) 71 (47.7) 
 Missing 25 (59.5) 25 (55.6) 19 (30.6) 69 (46.3) 
a
1 small-cell carcinoma (R2), 2 non-small cell carcinoma (R3), 2 neuroendocrine carcinoma (R1), 1 
oat cell (R1). The remainder were defined as adenocarcinoma or carcinoma. 
b
Includes 1 sarcoma extending into the fallopian tube.  
c
1 adenocarcinoma, (R1), the remainder hepatocellular carcinoma, including 1 fibrolamellar (R3).  
d
Other locations (R1, R2, R3): adrenocortical (1, 0, 0), alveolar (0, 1, 0), brain (0, 0, 2), chest (0, 1, 0), 
duodenum (1, 0, 0), eye (1, 5, 0), gastro-esophageal junction (0, 0, 2), jejunum (1, 0, 0), mediastinum 
(0, 0, 1), mouth (0, 1, 0), nasopharyngeal/nose (1, 1, 0), ocular (1, 0, 0), parotid (1, 0, 0), pelvis (0, 0, 
1), peritoneum (0, 1, 1), ribs (0, 1, 0), scalp (0, 1, 0), shoulder (1, 0, 0), peri-seminal vesicle (0, 0, 1), 
small bowel (1, 0, 1), thyroid (2, 0, 0), toe (0, 1, 0), tongue (0, 0, 1), urethra (0, 0, 1), uveal (1, 1, 0), 
and undefined (0, 1, 0).  
ECOG PS, Eastern Cooperative Oncology Group performance status. 
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Table 2. Treatment-related TEAEs  
 
Regimen 1 
(n = 42) 
Regimen 2 
(n = 45) 
Regimen 3 
(n = 62) 
Total 
(N = 149) 
Patients, n (%) Any grade Grade ≥3 Any grade Grade ≥3 Any grade Grade ≥3 Any grade Grade ≥3 
Treatment-related TEAEsa 14 (33.3) 1 (2.4) 23 (51.1) 3 (6.7) 39 (62.9) 9 (14.5) 76 (51.0) 13 (8.7) 
 Peripheral edema 1 (2.4) 0 2 (4.4) 0 16 (25.8) 3 (4.8) 19 (12.8) 3 (2.0) 
 Fatigue 3 (7.1) 0 5 (11.1) 0 11 (17.7) 2 (3.2) 19 (12.8) 2 (1.3) 
 Decreased appetite 2 (4.8) 0 0 0 10 (16.1) 0 12 (8.1) 0 
 Nausea 1 (2.4) 0 2 (4.4) 1 (2.2) 6 (9.7) 0 9 (6.0) 1 (0.7) 
 Vomiting 2 (4.8) 0 2 (4.4) 1 (2.2) 5 (8.1) 1 (1.6) 9 (6.0) 2 (1.3) 
 Lipase increased 1 (2.4) 1 (2.4) 4 (8.9) 2 (4.4) 1 (1.6) 0 6 (4.0) 3 (2.0) 
 Rash 0 0 2 (4.4) 0 2 (3.2) 0 4 (2.7) 0 
 AST increased 1 (2.4) 0 0 0 3 (4.8) 1 (1.6) 4 (2.7) 1 (0.7) 
 Diarrhea 0 0 1 (2.2) 0 3 (4.8) 0 4 (2.7) 0 
 ALT increased 0 0 0 0 3 (4.8) 2 (3.2) 3 (2.0) 2 (1.3) 
 Anemia 0 0 0 0 3 (4.8) 0 3 (2.0) 0 
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a
For any-grade treatment-related TEAEs, events occurring in >2 patients with any regimen are reported; for treatment-related TEAEs grade 3 or higher, all 
events are shown.  
ALT, alanine aminotransferase; AST, aspartate transaminase; TEAE, treatment-emergent adverse event. 
 
  
 Blood creatinine increased 0 0 0 0 3 (4.8) 0 3 (2.0) 0 
 Constipation 0 0 0 0 3 (4.8) 0 3 (2.0) 0 
 Transaminases increased 0 0 0 0 3 (4.8) 0 3 (2.0) 0 
 Peripheral neuropathy  1 (2.4) 0 1 (2.2) 0 1 (1.6) 0 3 (2.0) 0 
 Renal failure 2 (4.8) 0 0 0 1 (1.6) 0 3 (2.0) 0 
 Edema 0 0 0 0 1 (1.6) 1 (1.6) 1 (0.7) 1 (0.7) 
 Amylase increased 1 (2.4) 1 (2.4) 0 0 0 0 1 (0.7) 1 (0.7) 
 Hypoalbuminemia 0 0 0 0 2 (3.2) 1 (1.6) 2 (1.3) 1 (0.7) 
 Hyponatremia 0 0 0 0 2 (3.2) 1 (1.6) 2 (1.3) 1 (0.7) 
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Table 3. Best overall response, objective response rate, and clinical benefit 
rate by regimen  
Response 
Regimen 1 
(n = 42) 
Regimen 2 
(n = 45) 
Regimen 3 
(n = 62) 
Total 
(N = 149) 
Partial response, n (%) 0 0 2 (3.2) 2 (1.3)a 
Stable disease, n (%) 12 (28.6) 10 (22.2) 12 (19.4) 34 (22.8) 
Progressive disease, n 
(%) 
25 (59.5) 27 (60.0) 38 (61.3) 90 (60.4) 
Not evaluable, n (%) 5 (11.9) 8 (17.8) 10 (16.1) 23 (15.4) 
Objective response rate, 
n (%) [90% CI] 
0 
[0–6.9] 
0 
[0–6.4] 
2 (3.2) 
[0.6–9.8] 
2 (1.3) 
[0.2–4.2] 
Clinical benefit rate, n 
(%) [90% CI] 
12 (28.6) 
[17.4–42.1] 
10 (22.2) 
[12.6–34.8] 
14 (22.6) 
[14.2–33.0] 
36 (24.2) 
[18.5–30.6] 
a
Two further patients with a best overall response of stable disease (one each in regimen 2 and 
regimen 3) had an unconfirmed partial response. 
CI, confidence interval. 
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Table 4. Best overall response, objective response rate, and clinical benefit 
rate by tumor MET status  
Response 
 
MET IHC≤2 
(n = 73) 
MET IHC3+ 
(n = 16) 
Not amplified 
(n = 71) 
Amplified 
(n = 9) 
Partial response, n (%) 0 2 (12.5) 2 (2.8) 0 
Stable disease, n (%) 17 (23.3) 4 (25.0) 17 (23.9) 2 (22.2) 
Progressive disease, n 
(%) 
47 (64.4) 7 (43.8) 42 (59.2) 5 (55.6) 
Not evaluable, n (%) 9 (12.3) 3 (18.8) 10 (14.1) 2 (22.2) 
Objective response rate, 
n (%) [90% CI] 
0 
[0, 4.0] 
2 (12.5) 
[2.3 34.4] 
2 (2.8) 
[0.5, 8.6] 
0 
[0, 28.3] 
Clinical benefit rate, n 
(%) [90% CI] 
17 (23.3) 
[15.4, 32.9] 
6 (37.5) 
[17.8, 60.9] 
19 (26.8) 
[18.3, 36.7] 
2 (22.2) 
[4.1, 55.0] 
CI, confidence interval; IHC, immunohistochemistry. 
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Figures Legend 
Figure 1. Clinical study patient allocation and pharmacokinetic modeling 
A, Patient allocations and regimens.  
B, Workflow of pharmacokinetic model development. 
FIM, first-in-man; PD, pharmacodynamic; PK, pharmacokinetic; RP2D, recommended phase II dose. 
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Figure 2. Tumor growth inhibition and dose-dependent phospho-MET 
inhibition.  
A, Tumor growth inhibition in KP-4 cell-line xenograft tumors. Observed versus 
predicted tumor volumes after fitting the PK/efficacy model to tumor volume data 
(means from two independent experiments) from the KP-4 xenograft efficacy studies. 
B, Correlation of efficacy (% T/C) to PD modulation phospho-MET inhibition  
(Y
1234-1235
) in the KP-4 xenograft tumor model on the last day of the experiment, 
matching by dose regimen. Near-complete inhibition (≥95%) of phospho-MET is 
required for tumor stasis or regression. Using the PK/PD model, phospho-MET 
modulation was simulated under daily treatment conditions and at the doses tested 
in the efficacy experiments (5–200 mg/kg). The average phospho-MET over time 
was then calculated and plotted against % TGI. The black line represents the fit to 
the data and shows that tumor regression (% T/C >0) is achieved when mean 
phospho-MET is >95% over the treatment period. % T/C represents the tumor 
volume of treated groups in relation to control and is calculated according to: 
%∆T/∆C = (TVf - TVi/TVfCtrl – TViCtrl) x 100%]; where, TV = tumor volume, f = final, 
i = initial, Ctrl = control. 
C, Simulation of dose-dependent phospho-MET inhibition (relative to baseline) in 
humans. Left to right panel: tepotinib 300 mg, 500 mg, and 1000 mg once daily every 
other week, respectively. The solid black curve represents the time profile of 
population median prediction of percentage phospho-MET inhibition relative to 
baseline, and the shaded area represents a simulation-based 10–90% prediction 
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interval for phospho-MET inhibition relative to baseline. The dotted lines indicate the 
PD threshold of 95% phospho-MET inhibition. 
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